Altered whole-brain white matter networks in preclinical Alzheimer's disease

Altered whole-brain white matter networks in preclinical Alzheimer's disease

Surrogates of whole-brain white matter (WM) networks reconstructed using diffusion tensor imaging (DTI) are novel markers of structural brain connectivity. Global connectivity of networks has been found impaired in clinical Alzheimer's disease (AD) compared to cognitively healthy aging. We hypo...

Full description

Bibliographic Details
Main Authors:	Florian Udo Fischer, Dominik Wolf, Armin Scheurich, Andreas Fellgiebel
Format:	Article
Language:	English
Published:	Elsevier 2015-01-01
Series:	NeuroImage: Clinical
Subjects:	Preclinical Alzheimer's disease DTI Brain network
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213158215001138

Similar Items

Preclinical diagnosis of Alzheimer's disease: Prevention or prediction?
by: Ricardo Nitrini

Altered Homotopic Functional Connectivity Within White Matter in the Early Stages of Alzheimer’s Disease
by: Pan Wang, et al.
Published: (2021-09-01)

Specific Patterns of White Matter Alterations Help Distinguishing Alzheimer's and Vascular Dementia
by: Fulvia Palesi, et al.
Published: (2018-04-01)

An Algorithm for Preclinical Diagnosis of Alzheimer's Disease
by: Tapan K. Khan
Published: (2018-04-01)

Change in retinal structural anatomy during the preclinical stage of Alzheimer's disease
by: Cláudia Y. Santos, et al.
Published: (2018-01-01)

Reactions to learning a “not elevated” amyloid PET result in a preclinical Alzheimer’s disease trial
by: Joshua D. Grill, et al.
Published: (2018-12-01)

Early affective changes and increased connectivity in preclinical Alzheimer's disease
by: Carolyn A. Fredericks, et al.
Published: (2018-01-01)

Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndrome
by: Sigan L. Hartley, et al.
Published: (2020-01-01)

Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis
by: Carmen Peña-Bautista, et al.
Published: (2021-06-01)

Using the A/T/N Framework to Examine Driving in Preclinical Alzheimer’s Disease
by: Catherine M. Roe, et al.
Published: (2018-05-01)

Participant and study partner prediction and identification of cognitive impairment in preclinical Alzheimer’s disease: study partner vs. participant accuracy
by: Mary M. Ryan, et al.
Published: (2019-10-01)

Study partners should be required in preclinical Alzheimer’s disease trials
by: Joshua D. Grill, et al.
Published: (2017-12-01)

Evaluation of Naturalistic Driving Behavior Using In-Vehicle Monitoring Technology in Preclinical and Early Alzheimer’s Disease
by: Jennifer D. Davis, et al.
Published: (2020-10-01)

Nonvascular retinal imaging markers of preclinical Alzheimer's disease
by: Peter J. Snyder, et al.
Published: (2016-01-01)

Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease
by: Philip S. Insel, et al.
Published: (2017-05-01)

The Fornix in Mild Cognitive Impairment and Alzheimer’s Disease
by: Milap Anil Nowrangi, et al.
Published: (2015-01-01)

Seed Location Impacts Whole-Brain Structural Network Comparisons between Healthy Elderly and Individuals with Alzheimer’s Disease
by: Lauren Zajac, et al.
Published: (2017-04-01)

GPS driving: a digital biomarker for preclinical Alzheimer disease
by: Sayeh Bayat, et al.
Published: (2021-06-01)

The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease
by: Jessica B. Langbaum, et al.
Published: (2020-05-01)

Preclinical Alzheimer disease: Brain oxidative stress, Aβ peptide and proteomics
by: Christopher D. Aluise, et al.
Published: (2010-08-01)

Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease
by: Laurent Younes, et al.
Published: (2019-04-01)

Preclinical and clinical issues in Alzheimer’s disease drug research and development.
by: Cesare eMancuso, et al.
Published: (2014-10-01)

Linking white matter and deep gray matter alterations in premanifest Huntington disease
by: Andreia V. Faria, et al.
Published: (2016-01-01)

Radiomics Analysis of Magnetic Resonance Imaging Facilitates the Identification of Preclinical Alzheimer’s Disease: An Exploratory Study
by: Tao-Ran Li, et al.
Published: (2020-12-01)

Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials
by: Terry E. Goldberg, et al.
Published: (2015-03-01)

Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis
by: Lucilla Parnetti, et al.
Published: (2019-01-01)

Contralesional White Matter Alterations in Patients After Hemispherotomy
by: Jennifer Gaubatz, et al.
Published: (2020-07-01)

Preclinical and clinical issues in Alzheimer's disease drug research and development
Published: (2015)

Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease
by: Oriol Grau-Rivera, et al.
Published: (2021-02-01)

Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is indicative of Aβ-related cognitive impairment in preclinical Alzheimer’s disease after a 27-month delay interval
by: Jessica Alber, et al.
Published: (2020-03-01)

FRACTIONAL ANISOTROPY OF THE FORNIX AND HIPPOCAMPAL ATROPHY IN ALZHEIMER’S DISEASE
by: Kejal eKantarci
Published: (2014-11-01)

The meta-memory ratio: a new cohort-independent way to measure cognitive awareness in asymptomatic individuals at risk for Alzheimer’s disease
by: Geoffroy Gagliardi, et al.
Published: (2020-05-01)

Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease
by: Aubryn Samaroo, et al.
Published: (2020-01-01)

The Value of OCT and OCTA as Potential Biomarkers for Preclinical Alzheimer’s Disease: A Review Study
by: Inés López-Cuenca, et al.
Published: (2021-07-01)

Assessing risk for preclinical β‐amyloid pathology with APOE, cognitive, and demographic information
by: Philip S. Insel, et al.
Published: (2016-01-01)

Why Preclinical Imaging and What Will Happen in the Future?
by: Razieh Solgi, et al.
Published: (2021-03-01)

ALTERATIONS OF ZINC TRANSPORTERS IN ALZHEIMER'S DISEASE
by: Lyubartseva, Ganna
Published: (2009)

Tau-related white-matter alterations along spatially selective pathways
by: Qiuting Wen, et al.
Published: (2021-02-01)

Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals
by: Kok Pin Ng, et al.
Published: (2021-03-01)

The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions
by: Sterling C. Johnson, et al.
Published: (2018-01-01)

Cannot write session to /tmp/vufind_sessions/sess_hp58ruuaik62ecilnks6n7g623